Hualan Bio said on the interactive platform on April 14 that the company's intravenous human immunoglobulin (IVIG) (5%, 10%) has completed Phase III clinical research and submitted a drug registration and marketing authorization application to the National Drug Administration and has been accepted, and is in the drug approval stage; human coagulation factor IX (FIX) is conducting Phase III clinical research; Exendin-4-FC fusion protein project has completed Phase I clinical trials and is conducting Phase II clinical trials; the vaccine company is steadily carrying out preclinical research and development of recombinant herpes zoster vaccine (CHO cells), mRNA influenza virus vaccine, mRNA respiratory syncytial virus (RSV) vaccine, and poxvirus broad-spectrum influenza; freeze-dried group A and group C meningococcal conjugate vaccine has completed Phase III Phase III clinical trials are underway for Hib conjugate vaccine, which was submitted for clinical trials in December 2024 and accepted; Phase III clinical trials are underway for adsorbed acellular pertussis (three-component) tetanus combined vaccine, and Bevacizumab developed by Gene Company obtained the "Drug Registration Certificate" on November 21, 2024, and was approved for formal production and sales; Gene Company submitted an application for drug registration and marketing authorization for rituximab injection to the National Medical Products Administration and was accepted; Adalimumab, Trastuzumab, and Desuomab are in Phase III clinical trials; Ipilimumab and Panitumumab are in Phase I clinical trials; Recombinant anti-Claudin18.2 fully human monoclonal antibody injection, recombinant anti-PD-L1 and TGF-β bifunctional fusion protein injection, and recombinant anti-BCMA and CD3 bispecific antibody injection have obtained clinical approval and are awaiting clinical trials. The above projects can cultivate new profit growth points for the company and enrich the company's product lineup.https://finance.eastmoney.com/a/202504143376034257.html